| 0.928 0.038 (4.26%) | 09-26 15:55 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 1.14 |
1-year : | 1.24 |
| Resists | First : | 0.97 |
Second : | 1.07 |
| Pivot price | 0.9 |
|||
| Supports | First : | 0.82 |
Second : | 0.69 |
| MAs | MA(5) : | 0.9 |
MA(20) : | 0.91 |
| MA(100) : | 1.15 |
MA(250) : | 1.76 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 26.4 |
D(3) : | 23.8 |
| RSI | RSI(14): 52.3 |
|||
| 52-week | High : | 4.4 | Low : | 0.72 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ HOOK ] has closed below upper band by 18.4%. Bollinger Bands are 83.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 34 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.93 - 0.93 | 0.93 - 0.94 |
| Low: | 0.87 - 0.87 | 0.87 - 0.88 |
| Close: | 0.92 - 0.93 | 0.93 - 0.94 |
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in Phase I/II clinical trial for the treatment of human papillomavirus 16-positive cancers. The company's preclinical stage products include HB-300 program for prostate cancer; and HB-700 for targeting mutated KRAS in pancreatic, colorectal, and lung cancer. HOOKIPA Pharma Inc. has a collaboration with Gilead Sciences, Inc. to collaborate on preclinical research programs to evaluate potential vaccine products using or incorporating its replicating and non-replicating technology platforms for the treatment, cure, diagnosis, or prevention of Hepatitis B Virus. The company was incorporated in 2011 and is headquartered in New York, New York.
Fri, 18 Jul 2025
HOOKIPA Pharma to delist from Nasdaq amid asset sale to Gilead - Investing.com
Fri, 18 Jul 2025
HOOKIPA Pharma Announces Intention to Voluntarily Delist and Deregister its Common Stock - Yahoo Finance
Mon, 07 Apr 2025
Hookipa Pharma stock hits 52-week low at $0.81 amid sharp decline - Investing.com
Fri, 28 Feb 2025
HOOKIPA Pharma Inc. SEC 10-K Report - TradingView
Thu, 20 Feb 2025
HOOKIPA Pharma Inc. Announces Decision Against All-Share Acquisition of Poolbeg Pharma plc - Quiver Quantitative
Thu, 20 Feb 2025
UPDATE: US biotech Hookipa retracts merger plans with UK company - Fierce Biotech
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
OTC
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 10 (M) |
| Shares Float | 10 (M) |
| Held by Insiders | 19.2 (%) |
| Held by Institutions | 32.9 (%) |
| Shares Short | 36 (K) |
| Shares Short P.Month | 131 (K) |
| EPS | -5.85 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.71 |
| Profit Margin | 0 % |
| Operating Margin | -885.3 % |
| Return on Assets (ttm) | -45.3 % |
| Return on Equity (ttm) | -105.8 % |
| Qtrly Rev. Growth | -94.5 % |
| Gross Profit (p.s.) | -5.16 |
| Sales Per Share | 0.95 |
| EBITDA (p.s.) | -7.39 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -53 (M) |
| Levered Free Cash Flow | -33 (M) |
| PE Ratio | -0.16 |
| PEG Ratio | 0 |
| Price to Book value | 0.34 |
| Price to Sales | 0.97 |
| Price to Cash Flow | -0.18 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|